Regeneron Pharmaceuticals, Inc. REGN
NASDAQ · United States · Health Technology
$735.96-22.31 (-2.94%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Investing.com -- Shares of Sanofi jumped as much as 3.6% on Thursday before paring gains to trade 1.1% higher after the French drugmaker agreed to pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four long-acting medicines for inflammatory diseases.
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from RegeneronRegeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share dev
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Regeneron and Sanofi to host a conference
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels.
Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares today.
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.
Demy-Colton today announced the agenda for BioFuture™ 2026, taking place October 27–28 at Cure, 345 Park Avenue South in New York City. The conference will bring together leaders from across biopharma, healthcare, investment, technology and policy for discussions, company presentations, networking and one-to-one partnering, followed by virtual partnering November 3–5.
Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...
Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...
Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.